1. Home
  2. PRG vs AKRO Comparison

PRG vs AKRO Comparison

Compare PRG & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRG
  • AKRO
  • Stock Information
  • Founded
  • PRG 2020
  • AKRO 2017
  • Country
  • PRG United States
  • AKRO United States
  • Employees
  • PRG N/A
  • AKRO N/A
  • Industry
  • PRG Diversified Commercial Services
  • AKRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • PRG Consumer Discretionary
  • AKRO Health Care
  • Exchange
  • PRG Nasdaq
  • AKRO Nasdaq
  • Market Cap
  • PRG 2.0B
  • AKRO 2.4B
  • IPO Year
  • PRG N/A
  • AKRO 2019
  • Fundamental
  • Price
  • PRG $48.28
  • AKRO $32.38
  • Analyst Decision
  • PRG Strong Buy
  • AKRO Strong Buy
  • Analyst Count
  • PRG 6
  • AKRO 7
  • Target Price
  • PRG $52.60
  • AKRO $43.20
  • AVG Volume (30 Days)
  • PRG 362.2K
  • AKRO 554.0K
  • Earning Date
  • PRG 10-23-2024
  • AKRO 11-08-2024
  • Dividend Yield
  • PRG 0.99%
  • AKRO N/A
  • EPS Growth
  • PRG 8.67
  • AKRO N/A
  • EPS
  • PRG 3.58
  • AKRO N/A
  • Revenue
  • PRG $2,417,577,000.00
  • AKRO N/A
  • Revenue This Year
  • PRG $2.94
  • AKRO N/A
  • Revenue Next Year
  • PRG $6.29
  • AKRO N/A
  • P/E Ratio
  • PRG $13.48
  • AKRO N/A
  • Revenue Growth
  • PRG N/A
  • AKRO N/A
  • 52 Week Low
  • PRG $26.39
  • AKRO $13.86
  • 52 Week High
  • PRG $50.28
  • AKRO $37.00
  • Technical
  • Relative Strength Index (RSI)
  • PRG 57.67
  • AKRO 55.64
  • Support Level
  • PRG $46.61
  • AKRO $31.12
  • Resistance Level
  • PRG $49.72
  • AKRO $35.11
  • Average True Range (ATR)
  • PRG 1.39
  • AKRO 1.74
  • MACD
  • PRG 0.51
  • AKRO 0.11
  • Stochastic Oscillator
  • PRG 81.30
  • AKRO 53.31

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The Company has two reportable segments: (i) Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and (ii) Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the progressive leasing segment.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: